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Lupus miliaris disseminatus faciei (LMDF) is an
inflammatory dermatosis characterized by 1- to 3-
mm red-to-yellow-brown papules on the central and
lateral face, particularly on and around the eyelids.
Lesions can occur singly or in crops. The discrete
papules appear yellow-brown (‘‘apple-jelly’’) on
diascopy and as epithelioid cell granulomas histo-
logically, thus, resembling tuberculosis, sarcoidosis,
or other granulomatous diseases.1 LMDF classically
presents on the face; however, an increasing
number of cases are reported with extrafacial
involvement.1-6 We describe a unique presentation
of LMDF characterized predominantly by bilateral
axillae involvement.CASE
A healthy, 48-year-old white woman presented
with a persistent 2.5-month history of an asymptom-
atic, nonpruritic papular eruption in her bilateral
axillae and a similar but less robust eruption on the
lateral eyelids. She had a history of zirconium-based
antiperspirant deodorant and shaving cream use but
otherwise denied application of topical products to
her axillae. Physical examination found numerous
reddish-brown, firm, nonblanching, 2- to 3-mm
papules spread throughout the left axilla (Fig 1)
and right axilla. There were a few, very subtle, 2- to
3-mm skin-to-pink-colored papules around the
lateral canthi of both eyes, superiorly and inferiorly.
There was no appreciated lacrimal gland hypertro-
phy. Punch biopsies from the left superior axilla
(Figs 2 and 3) and left zygoma were performed.
Histopathologic analysis found dermal aggregates
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giant cells were noted and occasionally exhibited
phagocytosis of elastic fibers. Focal necrosis
occurred in some of the granulomas. Staining for
fungi and acid-fast bacilli was negative.
Given the granulomatous histology, the patient
underwent further workup for sarcoidosis, including
chest radiograph, complete blood count, compre-
hensive metabolic panel, and serum electrophoresis,
all of which were normal. Her tuberculin skin test
result was negative. She had no lymphadenopathy,
hepatosplenomegaly, lacrimal enlargement, or fam-
ily history of sarcoidosis. Clinicopathologic correla-
tion led to the final diagnosis of LMDF. The patient
was started on minocycline, 100 mg by mouth once
daily. She noted near complete resolution of the rash
12 months after therapy.DISCUSSION
The cause of LMDF remains unclear. In 1878, Fox7
reported on disseminated follicular lupus, and soon
after in 1903 Radcliffe-Crocker designated the term
acne agminata to describe the grouped eruptions of
discrete, dull red-brown papules, which spontane-
ously involuted leaving pigmented scars.8 Initially,
LMDF was considered a variant of lupus vulgaris or a
tuberculid, but Mycobacterium tuberculosis has not
been found in active lesions.9 LMDFwas proposed to
be a variant of sarcoidosis given its similar features
on diascopy; however, the variably present caseous660 S Euclid Ave, Campus Box 8123, St Louis, MO 63110.
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Fig 1. Diffuse red-brown 2- to 3-mm firm papules within
the axillary vault.
Fig 2. Histologic examination of a punch biopsy taken
from the patient’s left axilla shows aggregates of palisading
epithelioid cells, caseation necrosis, and multinucleated
giant cells. (Hematoxylin-eosin stain; original magnifica-
tion: 310.)
Fig 3. High-power view of multinucleated giant cells and
caseation necrosis (Hematoxylin-eosin stain; original
magnification: 340.)
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this. Others have highlighted the clinical overlap
between LMDF and granulomatous-type rosacea.
Although the conditions are quite similar, patients
with LMDF lack flushing and telangiectasia, have
eyelid involvement, and heal with scarring. Thus,
many now view LMDF as its own distinct rosacealike
syndrome.1
This patient’s clinical presentation is striking given
the predominate bilateral axillae involvement and
the very subtle, more classic facial manifestations.
Throughout the last 2 decades, there have been a
number of reported cases with extra-facial LMDF,
with most involving the neck, axillae, groin, or
extremities.1-6 Notably, in 2003, van de Scheur and
colleagues1 reported 3 different cases of LMDF, and,
as in our case, extrafacial lesions were prominent,
and a full workup for granulomatous skin diseases
was negative.2A variety of treatments for LMDF have been
attempted, but controlled studies are lacking, and
clinicians often find LMDF difficult to control.
Topical steroids are ineffective and are not recom-
mended for LMDF. Other reported therapies of
variable benefit include prednisone, injectable ste-
roids, tetracyclines, erythromycin, dapsone, clofazi-
mine, isotretinoin, and topical tacrolimus.3,10
Additionally, treatment-resistant LMDF responds to
fractioned laser and the 1450-nm diode laser.11
Active disease usually persists for 1 to 2 years and
resolves spontaneously, unfortunately with the po-
tential for disfiguring scarring.
In 2000, Skowron et al12 proposed a name change
from LMDF to FIGURE (facial idiopathic granulomas
with regressive evolution). To date, it does not
appear that this name change has been widely
used. Given the increasingly reported appearance
of LMDF in nonfacial sites, we propose that this
entity would be more suitably described as lupus
miliaris disseminatus. We are hopeful that this
knowledge leads to improved diagnostic acumen
and speedier identification of extrafacial lupus mil-
iaris disseminatus.
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